BR112018001438A2 - expressão de fgfr e suscetibilidade a um inibidor de fgfr - Google Patents

expressão de fgfr e suscetibilidade a um inibidor de fgfr

Info

Publication number
BR112018001438A2
BR112018001438A2 BR112018001438A BR112018001438A BR112018001438A2 BR 112018001438 A2 BR112018001438 A2 BR 112018001438A2 BR 112018001438 A BR112018001438 A BR 112018001438A BR 112018001438 A BR112018001438 A BR 112018001438A BR 112018001438 A2 BR112018001438 A2 BR 112018001438A2
Authority
BR
Brazil
Prior art keywords
gffr
subject
inhibitor
susceptibility
expression
Prior art date
Application number
BR112018001438A
Other languages
English (en)
Inventor
Vaslin- Chessex Anne
Moulon Corinne
Brichory Franck
Pokorska-Bocci Anna
Original Assignee
Debiopharm International S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm International S.A. filed Critical Debiopharm International S.A.
Publication of BR112018001438A2 publication Critical patent/BR112018001438A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

método para seleção de um indivíduo que sofre de um câncer para um regime terapêutico de administração de uma composição farmacêutica que compreende uma quantidade eficaz de um inibidor de fgfr, tal método compreende (1) a realização de uma biópsia de tumor ou líquido do indivíduo; (2) determinação do nível de expressão de quaisquer ou todos fgfr1, fgfr2 e fgfr3, e (3) comparação do nível de expressão determinado de pelo menos um dentre fgfr1, fgfr2 e fgfr3 com um valor limite pré-estabelecido, e declarar o indivíduo elegível para o regime terapêutico se o nível determinado exceder o valor limite. a invenção também se refere a um método de terapia de câncer personalizada que compreende a seleção de um indivíduo pelo método descrito acima e submeter o indivíduo a um regime terapêutico que compreende a administração de uma composição farmacêutica que compreende uma quantidade eficaz de um inibidor de fgfr.
BR112018001438A 2015-07-24 2016-07-21 expressão de fgfr e suscetibilidade a um inibidor de fgfr BR112018001438A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2015001245 2015-07-24
IB2016000290 2016-03-14
PCT/IB2016/001044 WO2017017516A1 (en) 2015-07-24 2016-07-21 Fgfr expression and susceptibility to an fgfr inhibitor

Publications (1)

Publication Number Publication Date
BR112018001438A2 true BR112018001438A2 (pt) 2018-12-04

Family

ID=56800307

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018001438A BR112018001438A2 (pt) 2015-07-24 2016-07-21 expressão de fgfr e suscetibilidade a um inibidor de fgfr

Country Status (13)

Country Link
US (1) US20180223371A1 (pt)
EP (2) EP3325661B1 (pt)
JP (1) JP2018524010A (pt)
KR (1) KR20180028524A (pt)
CN (1) CN108026588A (pt)
AU (1) AU2016300175A1 (pt)
BR (1) BR112018001438A2 (pt)
CA (1) CA2991846A1 (pt)
DK (1) DK3325661T3 (pt)
HK (1) HK1256118A1 (pt)
IL (1) IL256762A (pt)
RU (1) RU2728674C2 (pt)
WO (1) WO2017017516A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2756175T3 (es) 2013-12-27 2020-04-27 Chugai Pharmaceutical Co Ltd Genes mutantes guardián de fgfr y fármacos que se dirigen a los mismos
US10479780B2 (en) 2015-06-17 2019-11-19 Chugai Seiyaku Kabushiki Kaisha Aminopyrazole derivatives
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
KR20240014585A (ko) 2016-03-04 2024-02-01 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
EP3710595A1 (en) 2017-11-17 2020-09-23 Gen-Probe Incorporated Compositions and methods for detecting c1orf43 nucleic acid
WO2019181876A1 (ja) * 2018-03-19 2019-09-26 大鵬薬品工業株式会社 アルキル硫酸ナトリウムを含む医薬組成物
CN111455065B (zh) * 2019-08-22 2021-11-05 中国农业科学院植物保护研究所 Rpl19基因作为广聚萤叶甲内参基因的应用
EP3960875A1 (en) * 2020-08-28 2022-03-02 Koninklijke Philips N.V. Pcr method and kit for determining pathway activity
EP4134451A1 (en) * 2021-08-11 2023-02-15 Universität zu Köln Method for identifying responsiveness to fibroblast growth factor receptor 1 inhibitor therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2695950A (en) * 1952-05-14 1954-11-30 Neo Ray Products Inc Adjustable magnetically supported light
US5183284A (en) * 1990-09-20 1993-02-02 George Glenn Neis Coupling mechanism
EP2114941B1 (en) * 2006-12-22 2015-03-25 Astex Therapeutics Limited Bicyclic heterocyclic compounds as fgfr inhibitors
CN101600694A (zh) * 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
EP2132331B1 (en) * 2007-03-23 2016-08-03 The Translational Genomics Research Institute Method of classifying endometrial cancer
BR112012008094A2 (pt) 2009-08-07 2020-08-18 Chugai Seiyaku Kabushiki Kaisha derivado de aminopirazol, seu uso, composição farmacêutica que o compreende, agentes para inibir a atividade de fgfr e para prevenir ou tratar câncer
GB201020179D0 (en) * 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
CN104321058A (zh) * 2012-03-30 2015-01-28 诺华股份有限公司 用于治疗低磷血性疾病的fgfr抑制剂
EP2695950A1 (en) * 2012-08-10 2014-02-12 Blackfield AG Markers for responsiveness to an inhibitor of the fibroblast growth factor receptor
CA2908391A1 (en) * 2013-05-01 2014-11-06 Five Prime Therapeutics, Inc. Methods of treating cancer
ES2756175T3 (es) * 2013-12-27 2020-04-27 Chugai Pharmaceutical Co Ltd Genes mutantes guardián de fgfr y fármacos que se dirigen a los mismos

Also Published As

Publication number Publication date
RU2018104570A (ru) 2019-08-26
HK1256118A1 (zh) 2019-09-13
EP3325661B1 (en) 2019-10-16
EP3690059A1 (en) 2020-08-05
US20180223371A1 (en) 2018-08-09
WO2017017516A1 (en) 2017-02-02
IL256762A (en) 2018-03-29
EP3325661A1 (en) 2018-05-30
AU2016300175A1 (en) 2018-03-01
JP2018524010A (ja) 2018-08-30
CN108026588A (zh) 2018-05-11
KR20180028524A (ko) 2018-03-16
CA2991846A1 (en) 2017-02-02
RU2728674C2 (ru) 2020-07-30
RU2018104570A3 (pt) 2020-01-17
DK3325661T3 (da) 2020-01-20

Similar Documents

Publication Publication Date Title
BR112018001438A2 (pt) expressão de fgfr e suscetibilidade a um inibidor de fgfr
MX2023006766A (es) Composiciones que comprenden inhibidores de shp2 y metodos para tratar el cancer.
BR112016029041A8 (pt) uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico
BR112016029492A2 (pt) método para tratamento de linfoma não hodgkin
BR112018012914A2 (pt) composto, método para tratar, prevenir ou melhorar um ou mais sintomas de câncer, método para tratar, prevenir ou melhorar um ou mais sintomas de uma doença inflamatória e composição farmacêutica
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
NZ734594A (en) Bicyclic heterocycles as fgfr4 inhibitors
MX2018006217A (es) Agonistas del receptor de apelina y metodos de uso.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
BR112016019592A8 (pt) Composto, uso de um composto, e, composição farmacêutica
BR112019003533A2 (pt) terapia de combinação com inibidores de glutaminase
EA201791182A1 (ru) Новые производные 2'- и/или 5'-аминокислотных эфиров фосфороамидатов 3'-дезоксиаденозина в качестве противораковых соединений
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
MX2017011277A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
MX2023011608A (es) Metodos para inhibir ras.
BR112017013982A2 (pt) fármaco de combinação
BR112016024332A2 (pt) métodos para o tratamento, para a determinação dos compostos a serem utilizados, para a seleção de pacientes, para a monitoração da eficácia terapêutica, para a optimização da eficácia terapêutica, para a identificação de um biomarcador, artigo de fabricação, utilização de gdc-0941, gdc-0941 e um agente de terapia endócrina e composto para a utilização
BR112017027277A2 (pt) ?método para o tratamento ou prevenção de uma doença e métodos para matar uma célula?
BR112017014107A2 (pt) composição nutricional útil no tratamento de pacientes com ibd
BR112017025995A2 (pt) inibidor de igfbp3, composição farmacêutica para uso no tratamento e/ou prevenção de um distúrbio intestinal, método para o diagnóstico de um distúrbio intestinal em um indivíduo e kit para o diagnóstico de um distúrbio intestinal
BR112017025998A2 (pt) inibidor de eixo igfbp3/tmem219, composição farmacêutica para uso no tratamento e/ou prevenção de diabetes, método para identificar um indivíduo em risco de desenvolver diabetes tipo 1 e/ou tipo 2 ou para monitorar a resposta a um tratamento terapêutico em um indivíduo e kit
BR112017001971A2 (pt) ?métodos e composições para diagnosticar e tratar distúrbios inflamatórios intestinais?
BR112018004207A2 (pt) biomarcadores e métodos de tratamento de câncer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements